Elewski Boni E, Tosti Antonella
Department of Dermatology, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama;
J Clin Aesthet Dermatol. 2015 Nov;8(11):38-42.
A number of comorbidities and risk factors complicate the successful management of onychomycosis. Underlying conditions and patient characteristics, such as tinea pedis, age, and obesity, contribute to risk, whereas comorbidities, such as diabetes and psoriasis, can increase susceptibility to the disease. There are limited data on treatment effectiveness in these patients. Here, the authors review post hoc analyses of efinaconazole topical solution, 10%, in mild-to-moderate onychomycosis and present new data in terms of age and obesity. The only post hoc analysis to report significant differences so far is gender, where female patients do much better; however, the reasons are unclear. The authors report significant differences in terms of efficacy in obese patients who do not respond as well as those with normal body mass index (P=0.05) and in patients who have their co-existing tinea pedis treated compared to those in whom co-existing tinea pedis was not treated (P=0.025). Although there is a trend to reduced efficacy in older patients and those with co-existing diabetes, differences were not significant. More research is needed in onychomycosis patients with these important risk factors and comorbidities to fully evaluate the treatment challengse and possible solutions.
多种合并症和风险因素使甲癣的成功治疗变得复杂。潜在疾病和患者特征,如足癣、年龄和肥胖,会增加患病风险,而糖尿病和银屑病等合并症会增加对该病的易感性。关于这些患者的治疗效果的数据有限。在此,作者回顾了10%的艾氟康唑外用溶液治疗轻至中度甲癣的事后分析,并给出了关于年龄和肥胖的新数据。迄今为止,唯一报告有显著差异的事后分析是性别,女性患者的治疗效果要好得多;然而,原因尚不清楚。作者报告称,肥胖患者与体重指数正常的患者相比,疗效存在显著差异(P=0.05),同时,合并足癣接受治疗的患者与未接受治疗的患者相比,疗效也存在显著差异(P=0.025)。尽管老年患者和合并糖尿病的患者有疗效降低的趋势,但差异并不显著。对于患有这些重要风险因素和合并症的甲癣患者,需要开展更多研究,以全面评估治疗挑战和可能的解决方案。